药物信息为DRISDOL ERGOCALCIFEROL, USP 50,000 IU Capsule (sanofi-aventis U.S. LLC): ADVERSE REACTIONS
- CLINICAL PHARMACOLOGY
- INDICATIONS AND USAGE
- ADVERSE REACTIONS
- DOSAGE AND ADMINISTRATION
- HOW SUPPLIED
- PRINCIPAL DISPLAY PANEL - 1.25 mg capsule
- 外部链接相关的DRISDOL ERGOCALCIFEROL, USP 50,000 IU Capsule (sanofi-aventis U.S. LLC)
Hypervitaminosis D is characterized by effects on the following organ system:
Renal:Impairment of renal function with polyuria, nocturia, polydipsia, hypercalciuria, reversible azotemia, hypertension, nephrocalcinosis, generalized vascular calcification, or irreversible renal insufficiency which may result in death.
Soft Tissues:Widespread calcification of the soft tissues, including the heart, blood vessels, renal tubules, and lungs.
Skeletal:Bone demineralization (osteoporosis) in adults occurs concomitantly.
Decline in the average rate of linear growth and increased mineralization of bones in infants and children (dwarfism) vague aches, stiffness, and weakness.
Gastrointestinal:Nausea, anorexia, constipation.
Metabolic:Mild acidosis, anemia, weight loss.
- Drug Information Provided by National Library of Medicine (NLM).